The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by SRM/MRM assay. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and a designated protein is quantitated in the digest sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the described peptides. The proteins that can be detected and/or quantitated are CD3D, B7H3, B7-2, STAT1, GBP1, GPNMB, CD27, CD3E, and CD8.

Some embodiments include a genetically engineered cell comprising a nucleic acid encoding a detectable polypeptide operably linked to the Msi1 or Msi2 promoter and genetically engineered organisms comprising these genetically engineered cells.

The invention relates to the identification of taste receptors and cells which express these taste receptors which are involved in sweet and umami taste transduction. Also, the invention relates to the use of these taste receptors and cells which express these taste receptors in assays for the identification of taste modulatory compounds.

Provided herein are methods for characterizing pathogens based on data profiles generated by an analyzer. The provided methods allow for rapid identification and characterization of emergent pathogens or mutations by allowing for facile updates to the established pathogen data used by learning algorithms, while not altering the independent learning algorithms themselves.

Provided herein are methods for characterizing pathogens based on data profiles generated by an analyzer. The provided methods allow for rapid identification and characterization of emergent pathogens or mutations by allowing for facile updates to the established pathogen data used by learning algorithms, while not altering the independent learning algorithms themselves.

Provided herein are methods for determining the level of muscarinic acetylcholine receptor subtype-(M1 receptor) anticholinergic activity in a blood serum sample, the method comprising the steps of removing protein from the blood serum sample by treatment with perchloric acid (PCA) to produce a PCA-treated serum sample; incubating the PCA-treated serum sample with a membrane preparation from cultured cells expressing the M1 receptor and an M1 receptor ligand; detecting an amount of binding of the M1 receptor ligand to the M1 receptor and comparing the amount of binding to a standard to determine the level of M1 receptor anticholinergic activity in the blood serum sample. Also provided are kits for performing the method.

Provided herein are methods for determining the level of muscarinic acetylcholine receptor subtype-(M1 receptor) anticholinergic activity in a blood serum sample, the method comprising the steps of removing protein from the blood serum sample by treatment with perchloric acid (PCA) to produce a PCA-treated serum sample; incubating the PCA-treated serum sample with a membrane preparation from cultured cells expressing the M1 receptor and an M1 receptor ligand; detecting an amount of binding of the M1 receptor ligand to the M1 receptor and comparing the amount of binding to a standard to determine the level of M1 receptor anticholinergic activity in the blood serum sample. Also provided are kits for performing the method.

The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (binders), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.